TRCT
BIVI icon

Tower Research Capital (TRC)’s BioVie BIVI Stock Holding History

Tower Research Capital (TRC)’s Portfolio BIVI Stock Details BIVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4K Sell
2,064
-5,476
-73% -$8.6K ﹤0.01% 4437
2026
Q1 		$10.6K Buy
7,540
+6,923
+1,122% +$8.89K ﹤0.01% 3882
2025
Q4 		$716 Buy
+617
New +$993 ﹤0.01% 4836
2025
Q3 		– Sell
-462
Closed -$4.27K – 5232
2025
Q2 		$4.27K Sell
462
-79
-15% -$780 ﹤0.01% 4351
2025
Q1 		$5.3K Buy
541
+345
+176% +$5.51K ﹤0.01% 4134
2024
Q4 		$3.91K Sell
196
-132
-40% -$3.18K ﹤0.01% 4565
2024
Q3 		$3.94K Buy
328
+114
+53% +$3.63K ﹤0.01% 4734
2024
Q2 		$8.57K Buy
214
+91
+74% +$4.36K ﹤0.01% 4333
2024
Q1 		$6.5K Buy
123
+50
+68% +$5.13K ﹤0.01% 4359
2023
Q4 		$9.17K Sell
73
-148
-67% -$44.5K ﹤0.01% 4426
2023
Q3 		$75.3K Buy
221
+156
+240% +$61K ﹤0.01% 2205
2023
Q2 		$28.2K Buy
65
+22
+51% +$14.8K ﹤0.01% 3083
2023
Q1 		$35K Buy
43
+41
+2,050% +$27.2K ﹤0.01% 2834
2022
Q4 		$1K Sell
2
-57
-97% -$30.8K ﹤0.01% 5553
2022
Q3 		$15K Buy
59
+17
+40% +$4.04K ﹤0.01% 4156
2022
Q2 		$6K Buy
42
+34
+425% +$10.2K ﹤0.01% 4896
2022
Q1 		$4K Buy
+8
New +$2.95K ﹤0.01% 5180
2021
Q2 		– Sell
-3
Closed -$5K – 5472
2021
Q1 		$5K Buy
+3
New +$8.56K ﹤0.01% 4650

Other funds holding BIVI

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PTC
Philadelphia Trust Company Philadelphia, Pennsylvania $1.56B AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return

Tower Research Capital (TRC)'s BIVI Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its BioVie (BIVI) stake by 73% in Q2 2026, selling an estimated $8.6K and leaving 2,064 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #4437.

Tower Research Capital (TRC) first reported a position in BIVI in Q1 2021 and has held it in 18 quarters since. The position peaked at $75.3K in Q3 2023. 35 funds tracked by Wall St. Rank hold BIVI as of Q2 2026.

  • Tower Research Capital (TRC) held 2,064 shares of BioVie worth $4K as of Q2 2026.
  • Tower Research Capital (TRC) sold 5,476 BioVie shares in Q2 2026, an estimated $8.6K.
  • BioVie made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4437 holding.
  • Tower Research Capital (TRC) first reported a position in BioVie in Q1 2021 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s BioVie position peaked at $75.3K in Q3 2023.
  • 35 funds tracked by Wall St. Rank held BioVie as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.